Opinion|Videos|July 15, 2024
Dr Xu Provides Clinical Perspective on the CONTACT-03 Trial Outcomes
Wenxin (Vincent) Xu, MD, presents the findings from the phase 3 CONTACT-03 trial, which compared the efficacy of atezolizumab in combination with cabozantinib versus cabozantinib alone in patients with inoperable advanced renal cell carcinoma who had previously received immune checkpoint inhibitor treatment.
Advertisement
Episodes in this series
- Discuss results from the phase 3 CONTACT-03 trial (NCT04338269), evaluating atezolizumab + cabozantinib vs cabozantinib in inoperable aRCC after ICI treatment. (Pal, SK et al. Lancet. 2023; Choueiri T, et al. ASCO 2023. Abstract LBA4500)
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.
Adanma Ayanambakkam, MD, MS, discusses findings from the FIT-001 trial of darlifarnib plus cabozantinib in RCC.
UroGen submitted an NDA for UGN-103 in recurrent NMIBC, T-DXd improved PFS in first-line HER2-mutant lung cancer, and more.
In a phase 1/2 study, the LSD1 inhibitor bomedemstat reduced spleen volume, improved symptoms, and lowered driver mutation burden in patients with advanced myelofibrosis.
Neeta Somaiah, MD, discusses the significance of the Peak study and what an approval of bezuclastinib plus sunitinib would mean for GIST.
Sara Nunnery, MD, MSCI, and Irene M. Kang, MD, discuss toxicity and monitoring considerations for the use of ADCs in metastatic TNBC.
The NMPA accepted the NDA for the PD-L1/4-1BB–directed bispecific antibody opamtistomig in previously treated advanced extrapulmonary NEC.
Obesity can weaken the immune system and lead to disease progression, but Roswell Park experts revealed that exercise may reverse that effect.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma
2
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
3
The OncFive: Top Oncology Articles for the Week of 8/16
4
Darlifarnib Plus Cabozantinib Displays Early Signals of Safety and Efficacy in RCC
5